Regulatory aspects of safety pharmacology: past, present and future

被引:0
作者
Barbier, A [1 ]
机构
[1] Sanofi Synthelabo, Sanofi Rech, Dept Pharmacol Gen, F-34184 Montpellier 04, France
来源
THERAPIE | 2000年 / 55卷 / 01期
关键词
safety pharmacology; guidelines; Europe; USA; Japan; ICH;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Safety pharmacology, a discipline unrecognized until the last few years, is now the subject of Japanese, American, European and ICH draft guidelines. The aim of these guidelines, either of a general nature or targeted at one particular organ, is to define the necessary pharmacology studies as well as the conditions in which these studies must he performed to ensure the safe use of new molecules when they are administered to man. This presentation attempts to give a comparative analysis of these documents and to place them in the context of future international harmonization.
引用
收藏
页码:85 / 89
页数:5
相关论文
共 13 条
  • [1] [Anonymous], POINTS CONS ASS POT
  • [2] Committee for Proprietary Medicinal Products (CPMP), 1998, NOT GUID SAF PHARM S
  • [3] *CPMP, 1997, NOT GUID INV DRUG IN
  • [4] *CPMP, 1998, NOT GUID PRECL EV AN
  • [5] *CPMP, 1998, NOT GUID INV DRUG IN
  • [6] *CPMP, 1996, NOT GUID INV OST WOM
  • [7] *FDA, 1998, CONC PAP NONCL SAF P
  • [8] *FDA, 1994, GUID PRECL CLIN EV A
  • [9] *MIN HLTH WELF, 1998, GUID SAF PHARM STUD
  • [10] *MIN HLTH WELF, 1995, GUID GEN PHARM STUD